Fundraising FoxRiverVest Venture Partners — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsForesite CapitalLongwood FundNorwest Venture PartnersPivotal Life SciencesYsios Capitalabrdn plc+4 more
Bluejay is a biotechnology company focused on therapeutic development.
BiotechSan Mateo, US
Keting Chu(Founder, Chief Executive Officer and Chairman of the Board)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRA CapitalWellington ManagementFrazier Healthcare PartnersHBM Healthcare InvestmentsNovo Holdings+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.